Jurkat Xenograft Model Service for ALL

The Jurkat cell line provides a widely utilized and robust in vivo platform for investigating T-cell Acute lymphoblastic leukemia (ALL), facilitating deep insights into leukemia signaling pathways and therapeutic vulnerabilities. As a specialized pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision Jurkat Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your ALL drug discovery and development pipeline.

Overview of Jurkat Xenograft Model for ALL

The Jurkat xenograft model is an established in vivo translational system frequently employed in hematological oncology research for the study of T-cell ALL. By transplanting human Jurkat lymphoblasts into highly permissive, immunodeficient rodent hosts, this model effectively reproduces the systemic dissemination, aggressive marrow infiltration, and distinct peripheral blood pathophysiological profiles characteristic of human ALL.

Biologically, the Jurkat model is highly valued for its stable engraftment potential and the ability to replicate the rapid proliferation kinetics inherent in T-cell malignancies. The model preserves key human lymphoid molecular features, including lineage-specific marker expression and critical intracellular signaling cascades that regulate blast expansion. Consequently, the Jurkat model is extensively deployed in pre-clinical screening programs to assess the anti-leukemic potency of novel small-molecule inhibitors, monoclonal antibodies, and combination therapeutic regimens in a physiologically relevant in vivo setting.

Fig 1. LncRNA PPM1A-AS is up expressed in T-ALL. (Li G, et al., 2021)

Cell Line Information: Jurkat

The Jurkat cell line was derived from the peripheral blood of a patient diagnosed with T-cell ALL. These cells grow as suspension cultures under standard in vitro laboratory parameters, maintaining a stable lymphoblastoid phenotype that serves as a robust proxy for T-cell malignancy research.

Our Services

Workflow of Jurkat Xenograft Model Construction

• Cell Culture & Quality Control: Human Jurkat cells are expanded in vitro using certified nutrient suspension media under optimized growth parameters. STR authentication and mycoplasma clearance verification are completed prior to inoculation to ensure absolute phenotypic identity and biological purity.
• Host Selection & Acclimatization: Standardized, healthy immunodeficient mice (e.g., NSG or NOD/SCID strains to support hematological engraftment) are sourced from validated vendors. The animals undergo a dedicated acclimatization phase to stabilize baseline biological and physiological metrics.
• Precision Inoculation: A calibrated suspension of high-viability Jurkat cells is prepared in a sterile physiological buffer. The cellular suspension is precisely inoculated in vivo into the host cohorts via tail vein intravenous routes to facilitate systemic leukemic distribution.
• Longitudinal Growth Tracking: Following inoculation, disease progression is systematically monitored using FACS to detect human CD45+ cells or specific lymphoid markers (e.g., CD3) in peripheral blood. Animal weight, physical clinical indicators, and systemic disease burden are documented routinely.
• Stratification & Dosing: Once peripheral leukemic chimerism reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts to ensure balanced baseline systemic dimensions before the initiation of customized therapeutic dosing regimens.

Fig 2. Jurkat Xenograft Model Construction Workflow

Case Study - Jurkat Xenograft Model Development

A pre-clinical validation study was conducted using the Jurkat xenograft model to evaluate the therapeutic efficacy of a novel targeted inhibitor designed for ALL. Following precision intravenous inoculation of human Jurkat cells into immunodeficient mice, the animals exhibited steady, systemic leukemic engraftment and highly predictable disease progression across all study cohorts. Animals assigned to the active treatment group demonstrated a clear, statistically significant reduction in circulating leukemic blasts and prolonged survival times compared to the vehicle control, confirming the model's high sensitivity and predictive reliability for screening targeted T-cell ALL therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing diverse hematological and lymphoid lineages, providing highly reproducible in vivo translational platforms for complex leukemia research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive FACS metrics and robust statistical validations.

Contact us

Accelerating your ALL pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our Jurkat platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.